SINGAPORE – Media OutReach Newswire – January 16, 2024 – Zuellig Pharma, a leading healthcare solutions company in Asia, announced its marketing partnership with pharmaceutical company Substipharm Biologics, to expand access to the IMOJEV® vaccine against Japanese encephalitis in nine markets in Asia, including Brunei. , Cambodia, Hong Kong, Malaysia, Myanmar, Philippines, Singapore, Taiwan and Vietnam.
Japanese encephalitis (JE) is transmitted by mosquitoes and causes inflammation of the brain and is the leading cause of vaccine-preventable encephalitis in Asia. The disease currently has no treatment apart from the preventive protection provided by the JE vaccine such as IMOJEV®.
Under the terms of the agreement, Zuellig Pharma will provide marketing and distribution support for IMOJEV® JE vaccine for Substipharm Biologics in Singapore, Hong Kong, Malaysia, Philippines, Vietnam, Cambodia and Myanmar. In addition to the current warehousing and distribution (W&D) agreement with Substipharm Biologics for Brunei and Thailand, Zuellig Pharma will now also provide W&D support as well as sales and marketing to Substipharm Biologics in Taiwan. This is enhanced by the capabilities of ZP Therapeutics, a division of Zuellig Pharma, which has deep and market-proven expertise in improving access to healthcare products in Asia.
“As a leading healthcare solutions company, we are committed to expanding access to healthcare and meeting the changing healthcare needs in the region. This partnership with Substipharm Biologics is another testament to our commitment to providing access to affordable, high-quality vaccines to the communities around us. the region, supported by our strong understanding of the healthcare landscape in Asia,” said John Graham, CEO of Zuellig Pharma.
“ZP Therapeutics’ partnership with Substipharm Biologics is an important milestone as it expands the availability of IMOJEV® to patients across Asia. Our experience and deep vaccine expertise will enable us to provide critical support to physicians for this preventative JE vaccine, particularly for working populations in rural areas, where JE poses a serious threat,” commented Rehan Saghir, executive vice president of ZP Therapeutics.
“As a partner sharing our vision of providing patients with affordable, high-quality medicines and healthcare solutions, Substipharm Biologics will work closely with Zuellig Pharma to ensure that we continue to provide innovative and life-saving products to populations. from Asia and around the world. declared Fabrice Baschiera, Substipharm Biologics SA, Managing Director.
The IMOJEV® vaccine had already been acquired by Substipharm SAS from Sanofi in 2022, with the company committed to investing in expanding the availability of the vaccine globally.
https://www.zelligpharma.com/
https://sg.linkedin.com/company/zuellig-pharma
Hashtag: #ZuelligPharma #Substipharm #Vaccines #Distribution #Pharmaceuticals
The issuer is solely responsible for the content of this announcement.
